Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868699 | 0.82 | CYP11B1 (0.48) | CYP11B1CYP11B2NOTUMNPC1TP53 | |
| SCHEMBL868010 | 0.81 | CYP11B1 (0.53) | CYP11B1CYP11B2NOTUMHSD17B3 | |
| SCHEMBL14576479 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2NOTUMHSD17B3 | |
| SCHEMBL6925694 | 0.77 | CYP11B1 (0.46) | CYP11B1CYP11B2NOTUMMAPTLMNA | |
| SCHEMBL10198747 | 0.68 | CYP11B1 (0.50) | CYP11B1CYP11B2NOTUMNPC1TP53 | |
| SCHEMBL10198746 | 0.67 | CYP11B1 (0.43) | CYP11B1CYP11B2NOTUMMAPT | |
| SCHEMBL171240 | 0.67 | GRM2 (0.58) | — | |
| SCHEMBL5780390 | 0.67 | ALDH1A1 (0.70) | CYP11B1CYP11B2NOTUMNPC1TP53 | |
| SCHEMBL3457235 | 0.66 | NOTUM (0.65) | CYP11B1CYP11B2NOTUMNPC1TP53 | |
| SCHEMBL4740743 | 0.66 | CYP11B1 (0.63) | CYP11B1CYP11B2NOTUMHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | CYP11B1 341/4885CYP11B2 1031/4885NOTUM 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.